Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tiagabine: the safety landscape

I E Leppik1

  • 1Department of Neurology, University of Minnesota, Minneapolis, USA.

Epilepsia
|January 1, 1995
PubMed
Summary

Tiagabine (TGB) hydrochloride, a new antiepileptic drug, was well-tolerated in patients with difficult-to-control epilepsy. Adverse events were generally mild, transient, and infrequent, supporting its potential as an add-on therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effect of topiramate plasma concentration on linguistic behavior, verbal recall and working memory.

Epilepsy & behavior : E&B·2012
Same author

Double-masked, placebo-controlled study of intravenous levetiracetam for the treatment of status epilepticus and acute repetitive seizures in dogs.

Journal of veterinary internal medicine·2012
Same author

Steady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: effects of race and sex.

Clinical pharmacology and therapeutics·2012
Same author

Zonisamide discontinuation due to psychiatric and cognitive adverse events: a case-control study.

Neurology·2010
Same author

Phenytoin half-life and clearance during maintenance therapy in adults and elderly patients with epilepsy.

Neurology·2008
Same author

Intramuscular, intravenous and oral levetiracetam in dogs: safety and pharmacokinetics.

Journal of veterinary pharmacology and therapeutics·2008

Area of Science:

  • Neurology
  • Clinical Pharmacology
  • Pharmacovigilance

Background:

  • Tiagabine (TGB) hydrochloride is an investigational antiepileptic drug (AED).
  • Epilepsy often presents with difficult-to-control seizures, necessitating novel therapeutic options.

Purpose of the Study:

  • To evaluate the safety and tolerability of Tiagabine (TGB) hydrochloride.
  • To assess adverse events associated with TGB as an add-on therapy in epilepsy patients.

Main Methods:

  • Integrated safety analysis of five double-blind, add-on therapy trials.
  • Involved approximately 1,000 patients with epilepsy and difficult-to-control seizures.
  • Total human exposure of 1,810 patient-years.

Main Results:

  • TGB was generally well-tolerated, with infrequent discontinuation due to adverse events (15% vs. 5% for placebo).
  • Most common adverse event was transient dizziness; others included asthenia, nervousness, tremor, diarrhea, and depression.
  • Adverse events were typically mild to moderate, transient, and dose-titration related.
  • Long-term and short-term study adverse event profiles were comparable; serious and idiosyncratic events were uncommon.

Conclusions:

  • Tiagabine (TGB) hydrochloride demonstrates a favorable safety profile in patients with difficult-to-control epilepsy.
  • TGB is a potentially effective and tolerable add-on therapy for epilepsy management.
  • Further clinical development is supported by the observed safety and tolerability data.

Related Experiment Videos